| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Diseases | 18 | 2021 | 122 | 2.000 |
Why?
|
| Dermatology | 7 | 2021 | 75 | 1.600 |
Why?
|
| Skin Neoplasms | 13 | 2022 | 375 | 1.060 |
Why?
|
| Periodicals as Topic | 2 | 2016 | 158 | 0.830 |
Why?
|
| Dermatologic Agents | 7 | 2008 | 32 | 0.740 |
Why?
|
| Skin | 7 | 2016 | 451 | 0.560 |
Why?
|
| Psoriasis | 6 | 2017 | 46 | 0.530 |
Why?
|
| Melanoma | 6 | 2022 | 335 | 0.500 |
Why?
|
| Betacoronavirus | 3 | 2020 | 116 | 0.480 |
Why?
|
| Sclerema Neonatorum | 1 | 2014 | 2 | 0.480 |
Why?
|
| Progeria | 1 | 2014 | 6 | 0.480 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 143 | 0.430 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 154 | 0.430 |
Why?
|
| Quality Improvement | 1 | 2016 | 413 | 0.420 |
Why?
|
| Keratinocytes | 4 | 2019 | 68 | 0.410 |
Why?
|
| Internet | 1 | 2013 | 390 | 0.360 |
Why?
|
| Dermatomycoses | 2 | 2008 | 17 | 0.360 |
Why?
|
| Humans | 73 | 2022 | 68618 | 0.350 |
Why?
|
| Pyrimidines | 3 | 2019 | 178 | 0.350 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2009 | 15 | 0.330 |
Why?
|
| Registries | 6 | 2021 | 733 | 0.330 |
Why?
|
| Blastomyces | 1 | 2008 | 1 | 0.320 |
Why?
|
| Blastomycosis | 1 | 2008 | 1 | 0.320 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2008 | 7 | 0.320 |
Why?
|
| Pyrroles | 2 | 2019 | 83 | 0.300 |
Why?
|
| Piperidines | 2 | 2019 | 123 | 0.300 |
Why?
|
| Herpes Simplex | 4 | 2021 | 35 | 0.300 |
Why?
|
| Alopecia Areata | 4 | 2000 | 17 | 0.300 |
Why?
|
| Burkitt Lymphoma | 1 | 2006 | 18 | 0.270 |
Why?
|
| Neoplasms | 3 | 2019 | 1667 | 0.260 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2003 | 10 | 0.250 |
Why?
|
| Herpes Zoster | 2 | 2021 | 43 | 0.250 |
Why?
|
| Panniculitis, Nodular Nonsuppurative | 2 | 2002 | 2 | 0.230 |
Why?
|
| Panniculitis | 1 | 2002 | 7 | 0.210 |
Why?
|
| Diagnosis, Differential | 4 | 2014 | 1140 | 0.200 |
Why?
|
| Antiviral Agents | 4 | 1998 | 211 | 0.200 |
Why?
|
| Chickenpox | 1 | 2021 | 14 | 0.200 |
Why?
|
| Exanthema | 1 | 2021 | 30 | 0.190 |
Why?
|
| Drug Eruptions | 1 | 2021 | 16 | 0.190 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2021 | 4 | 0.190 |
Why?
|
| Eyelid Neoplasms | 1 | 2021 | 12 | 0.190 |
Why?
|
| Chilblains | 1 | 2020 | 1 | 0.180 |
Why?
|
| Mesenteric Cyst | 1 | 2000 | 1 | 0.180 |
Why?
|
| Crowdsourcing | 1 | 2020 | 8 | 0.180 |
Why?
|
| Administration, Topical | 5 | 2000 | 111 | 0.180 |
Why?
|
| Male | 23 | 2021 | 37321 | 0.180 |
Why?
|
| Arthritis, Psoriatic | 1 | 2019 | 3 | 0.170 |
Why?
|
| Lipids | 2 | 2019 | 298 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 84 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 62 | 0.160 |
Why?
|
| Forecasting | 2 | 2016 | 277 | 0.160 |
Why?
|
| Tacrolimus | 1 | 2000 | 127 | 0.160 |
Why?
|
| Clinical Medicine | 1 | 1998 | 20 | 0.150 |
Why?
|
| Drug Compounding | 1 | 1998 | 34 | 0.150 |
Why?
|
| Antifungal Agents | 3 | 2008 | 108 | 0.150 |
Why?
|
| Female | 24 | 2021 | 38074 | 0.140 |
Why?
|
| Calcitriol | 1 | 1997 | 106 | 0.140 |
Why?
|
| United States | 6 | 2022 | 7367 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 331 | 0.140 |
Why?
|
| Middle Aged | 15 | 2021 | 21147 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 46 | 0.140 |
Why?
|
| Herpesviridae Infections | 2 | 1990 | 23 | 0.140 |
Why?
|
| Adult | 16 | 2021 | 21403 | 0.130 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3259 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2000 | 514 | 0.130 |
Why?
|
| Inosine Pranobex | 3 | 1991 | 3 | 0.130 |
Why?
|
| Langerhans Cells | 3 | 1988 | 10 | 0.130 |
Why?
|
| Gadolinium | 1 | 2016 | 88 | 0.130 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2019 | 40 | 0.130 |
Why?
|
| Carcinoma | 1 | 2016 | 215 | 0.120 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 940 | 0.120 |
Why?
|
| Spectrum Analysis | 1 | 2014 | 81 | 0.120 |
Why?
|
| Keratosis | 2 | 2008 | 17 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 1851 | 0.110 |
Why?
|
| Ochronosis | 1 | 1993 | 1 | 0.110 |
Why?
|
| Hydroquinones | 1 | 1993 | 15 | 0.110 |
Why?
|
| Facial Dermatoses | 1 | 1993 | 14 | 0.110 |
Why?
|
| Contrast Media | 1 | 2016 | 595 | 0.110 |
Why?
|
| Acyclovir | 2 | 1990 | 38 | 0.100 |
Why?
|
| Pandemics | 3 | 2020 | 352 | 0.100 |
Why?
|
| Publishing | 1 | 2013 | 89 | 0.100 |
Why?
|
| Risk Factors | 5 | 2020 | 5731 | 0.100 |
Why?
|
| Vasculitis | 2 | 2002 | 33 | 0.100 |
Why?
|
| Aged | 10 | 2022 | 14862 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2019 | 7029 | 0.090 |
Why?
|
| Dermatitis, Atopic | 1 | 1989 | 17 | 0.090 |
Why?
|
| Medical History Taking | 2 | 2020 | 94 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2014 | 2455 | 0.080 |
Why?
|
| HIV | 1 | 1989 | 56 | 0.080 |
Why?
|
| Medicare | 2 | 2022 | 319 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 629 | 0.080 |
Why?
|
| Virus Replication | 1 | 1989 | 104 | 0.080 |
Why?
|
| Mycosis Fungoides | 3 | 1986 | 16 | 0.080 |
Why?
|
| T-Lymphocytes | 6 | 1985 | 597 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 123 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2008 | 1174 | 0.080 |
Why?
|
| Nail Diseases | 2 | 1999 | 13 | 0.080 |
Why?
|
| Biopsy, Needle | 2 | 2008 | 191 | 0.080 |
Why?
|
| Nutrition Surveys | 2 | 2020 | 208 | 0.080 |
Why?
|
| Receptors, CCR6 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Receptors, CCR7 | 1 | 2008 | 5 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2019 | 2007 | 0.080 |
Why?
|
| Receptors, CXCR4 | 1 | 2008 | 48 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 792 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1989 | 234 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 1 | 1988 | 101 | 0.070 |
Why?
|
| Galactosylgalactosylglucosylceramidase | 1 | 2007 | 39 | 0.070 |
Why?
|
| Amidohydrolases | 1 | 2007 | 60 | 0.070 |
Why?
|
| Skin Absorption | 3 | 1997 | 7 | 0.070 |
Why?
|
| Biopsy | 2 | 2006 | 540 | 0.070 |
Why?
|
| Young Adult | 4 | 2020 | 5717 | 0.070 |
Why?
|
| Karyotyping | 1 | 2006 | 74 | 0.070 |
Why?
|
| Incidence | 2 | 2020 | 1603 | 0.060 |
Why?
|
| Minoxidil | 1 | 1985 | 4 | 0.060 |
Why?
|
| Polyarteritis Nodosa | 2 | 2002 | 9 | 0.060 |
Why?
|
| Physicians | 1 | 1988 | 324 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1553 | 0.060 |
Why?
|
| Patient Selection | 1 | 2008 | 592 | 0.060 |
Why?
|
| Sunlight | 1 | 1984 | 59 | 0.060 |
Why?
|
| Calcium | 1 | 2007 | 929 | 0.060 |
Why?
|
| Immunity, Cellular | 6 | 1984 | 80 | 0.050 |
Why?
|
| Glucocorticoids | 2 | 1998 | 222 | 0.050 |
Why?
|
| Immunotherapy | 2 | 1982 | 215 | 0.050 |
Why?
|
| Prognosis | 3 | 2003 | 2093 | 0.050 |
Why?
|
| Histiocytes | 1 | 2002 | 8 | 0.050 |
Why?
|
| Acne Vulgaris | 2 | 1998 | 11 | 0.050 |
Why?
|
| Eosinophilia-Myalgia Syndrome | 1 | 2002 | 24 | 0.050 |
Why?
|
| Time Factors | 3 | 2020 | 4655 | 0.050 |
Why?
|
| Thrombophlebitis | 1 | 2002 | 47 | 0.050 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1982 | 14 | 0.050 |
Why?
|
| Scleroderma, Localized | 1 | 2002 | 19 | 0.050 |
Why?
|
| Fasciitis | 1 | 2002 | 30 | 0.050 |
Why?
|
| Pemphigoid, Bullous | 1 | 1982 | 13 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2022 | 45 | 0.050 |
Why?
|
| Cell Division | 2 | 2007 | 541 | 0.050 |
Why?
|
| Epidermolysis Bullosa | 1 | 1981 | 2 | 0.050 |
Why?
|
| Eosinophilia | 1 | 2002 | 47 | 0.050 |
Why?
|
| Porphyrias | 1 | 1981 | 3 | 0.050 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 1981 | 12 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2021 | 12 | 0.050 |
Why?
|
| Pityriasis Rubra Pilaris | 2 | 1997 | 2 | 0.050 |
Why?
|
| Simplexvirus | 1 | 2021 | 26 | 0.050 |
Why?
|
| Dermatitis Herpetiformis | 1 | 1981 | 3 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 87 | 0.050 |
Why?
|
| Pemphigus | 1 | 1981 | 12 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 1998 | 1745 | 0.050 |
Why?
|
| Mohs Surgery | 1 | 2021 | 16 | 0.050 |
Why?
|
| Foot Dermatoses | 2 | 1998 | 12 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 39 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 1980 | 14 | 0.050 |
Why?
|
| Staining and Labeling | 3 | 2008 | 144 | 0.050 |
Why?
|
| Global Health | 1 | 2021 | 136 | 0.050 |
Why?
|
| Connective Tissue Diseases | 1 | 1980 | 18 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2020 | 31 | 0.040 |
Why?
|
| Adolescent | 5 | 2020 | 8912 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 60 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 189 | 0.040 |
Why?
|
| Foot | 1 | 2020 | 66 | 0.040 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 1979 | 12 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 88 | 0.040 |
Why?
|
| Gold | 1 | 1980 | 76 | 0.040 |
Why?
|
| Hand | 1 | 2020 | 90 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 1999 | 32 | 0.040 |
Why?
|
| Alopecia | 3 | 1987 | 45 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 148 | 0.040 |
Why?
|
| Disease Progression | 1 | 2003 | 1038 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2000 | 216 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1980 | 186 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2022 | 7277 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 1999 | 104 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2007 | 1034 | 0.040 |
Why?
|
| Radiography | 1 | 2000 | 572 | 0.040 |
Why?
|
| Phototherapy | 1 | 1998 | 28 | 0.040 |
Why?
|
| Onychomycosis | 1 | 1998 | 6 | 0.040 |
Why?
|
| Fluconazole | 1 | 1998 | 26 | 0.040 |
Why?
|
| Absorption | 1 | 1998 | 49 | 0.040 |
Why?
|
| Dermatitis | 1 | 1998 | 28 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2000 | 453 | 0.040 |
Why?
|
| Aging | 1 | 1984 | 911 | 0.040 |
Why?
|
| Arthritis, Reactive | 1 | 1997 | 1 | 0.040 |
Why?
|
| Ichthyosis | 1 | 1997 | 3 | 0.040 |
Why?
|
| Ointments | 1 | 1997 | 15 | 0.040 |
Why?
|
| Biomarkers | 2 | 2017 | 1593 | 0.040 |
Why?
|
| Hand Dermatoses | 1 | 1997 | 10 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2020 | 403 | 0.040 |
Why?
|
| Child | 4 | 2000 | 6405 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 1997 | 34 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 880 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 1999 | 194 | 0.040 |
Why?
|
| Antigen-Antibody Complex | 3 | 1982 | 175 | 0.030 |
Why?
|
| Inosine | 2 | 1987 | 6 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1619 | 0.030 |
Why?
|
| Drug Resistance | 2 | 1990 | 223 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2008 | 682 | 0.030 |
Why?
|
| Precancerous Conditions | 2 | 2008 | 74 | 0.030 |
Why?
|
| Double-Blind Method | 4 | 1998 | 1738 | 0.030 |
Why?
|
| Urticaria Pigmentosa | 2 | 1986 | 5 | 0.030 |
Why?
|
| Orbital Neoplasms | 1 | 1993 | 21 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 1986 | 106 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 2358 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2016 | 219 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1980 | 756 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2008 | 306 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 1993 | 56 | 0.030 |
Why?
|
| Angioedema | 1 | 1993 | 41 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 2 | 1984 | 83 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 3705 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2014 | 159 | 0.030 |
Why?
|
| DNA | 3 | 1985 | 597 | 0.030 |
Why?
|
| South Carolina | 1 | 2019 | 2752 | 0.030 |
Why?
|
| Sezary Syndrome | 2 | 1982 | 3 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 1993 | 92 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 371 | 0.030 |
Why?
|
| Dinitrochlorobenzene | 2 | 1982 | 3 | 0.030 |
Why?
|
| Kidney | 1 | 2016 | 945 | 0.020 |
Why?
|
| Methotrexate | 2 | 1982 | 91 | 0.020 |
Why?
|
| Interferons | 2 | 1982 | 36 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 689 | 0.020 |
Why?
|
| Tretinoin | 2 | 1982 | 92 | 0.020 |
Why?
|
| Pruritus | 2 | 1981 | 35 | 0.020 |
Why?
|
| HIV Seropositivity | 1 | 1991 | 66 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1753 | 0.020 |
Why?
|
| Photochemotherapy | 2 | 1981 | 59 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 4848 | 0.020 |
Why?
|
| Raynaud Disease | 2 | 1980 | 24 | 0.020 |
Why?
|
| Viral Vaccines | 1 | 1989 | 17 | 0.020 |
Why?
|
| Retroviridae Infections | 1 | 1989 | 7 | 0.020 |
Why?
|
| United States Federal Trade Commission | 1 | 1988 | 1 | 0.020 |
Why?
|
| Lymphocyte Activation | 3 | 1985 | 397 | 0.020 |
Why?
|
| Legislation, Drug | 1 | 1988 | 9 | 0.020 |
Why?
|
| Consumer Product Safety | 1 | 1988 | 32 | 0.020 |
Why?
|
| Rosette Formation | 2 | 1985 | 9 | 0.020 |
Why?
|
| Pharmacy | 1 | 1988 | 26 | 0.020 |
Why?
|
| PUVA Therapy | 2 | 1994 | 2 | 0.020 |
Why?
|
| Recurrence | 1 | 1990 | 948 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2007 | 84 | 0.020 |
Why?
|
| Ceramidases | 1 | 2007 | 47 | 0.020 |
Why?
|
| Alkaline Ceramidase | 1 | 2007 | 35 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2008 | 130 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 95 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 1988 | 135 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 2223 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 234 | 0.020 |
Why?
|
| Acid Ceramidase | 1 | 2007 | 85 | 0.020 |
Why?
|
| Apudoma | 1 | 1986 | 1 | 0.020 |
Why?
|
| Hormones, Ectopic | 1 | 1986 | 1 | 0.020 |
Why?
|
| Gardner Syndrome | 1 | 1986 | 3 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2007 | 148 | 0.020 |
Why?
|
| Acanthosis Nigricans | 1 | 1986 | 4 | 0.020 |
Why?
|
| Paget Disease, Extramammary | 1 | 1986 | 5 | 0.020 |
Why?
|
| Paget's Disease, Mammary | 1 | 1986 | 4 | 0.020 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1986 | 12 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2008 | 447 | 0.020 |
Why?
|
| Carcinoid Tumor | 1 | 1986 | 20 | 0.020 |
Why?
|
| Sarcoma, Kaposi | 1 | 1986 | 25 | 0.020 |
Why?
|
| Skin Diseases, Infectious | 1 | 1986 | 16 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 282 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1988 | 402 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 1988 | 322 | 0.020 |
Why?
|
| Lymphoma | 1 | 1986 | 116 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 434 | 0.020 |
Why?
|
| Leukemia | 1 | 1986 | 117 | 0.020 |
Why?
|
| Leukocyte Migration-Inhibitory Factors | 1 | 1985 | 2 | 0.020 |
Why?
|
| Cell Migration Inhibition | 1 | 1985 | 8 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 1985 | 16 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 1985 | 29 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1040 | 0.020 |
Why?
|
| Concanavalin A | 1 | 1985 | 22 | 0.020 |
Why?
|
| Random Allocation | 2 | 1987 | 442 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1984 | 13 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 1984 | 63 | 0.010 |
Why?
|
| Cell Count | 1 | 1984 | 248 | 0.010 |
Why?
|
| Ceramides | 1 | 2007 | 578 | 0.010 |
Why?
|
| Griseofulvin | 1 | 1983 | 1 | 0.010 |
Why?
|
| Idoxuridine | 1 | 1983 | 4 | 0.010 |
Why?
|
| Prednisolone | 1 | 1983 | 23 | 0.010 |
Why?
|
| Triamcinolone | 1 | 1983 | 11 | 0.010 |
Why?
|
| Autoantibodies | 2 | 1984 | 434 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1983 | 30 | 0.010 |
Why?
|
| Lidocaine | 1 | 1983 | 36 | 0.010 |
Why?
|
| Neuralgia | 1 | 1983 | 27 | 0.010 |
Why?
|
| Chemotactic Factors, Eosinophil | 1 | 1982 | 2 | 0.010 |
Why?
|
| Basement Membrane | 1 | 1982 | 48 | 0.010 |
Why?
|
| Transfer Factor | 1 | 1982 | 1 | 0.010 |
Why?
|
| Cholera Vaccines | 1 | 1982 | 1 | 0.010 |
Why?
|
| Dinitrofluorobenzene | 1 | 1982 | 2 | 0.010 |
Why?
|
| Levamisole | 1 | 1982 | 4 | 0.010 |
Why?
|
| BCG Vaccine | 1 | 1982 | 12 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1982 | 95 | 0.010 |
Why?
|
| Melanocyte-Stimulating Hormones | 1 | 1982 | 3 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1987 | 848 | 0.010 |
Why?
|
| Skin Tests | 1 | 1982 | 30 | 0.010 |
Why?
|
| Dermatitis, Contact | 1 | 1982 | 14 | 0.010 |
Why?
|
| Nitrosourea Compounds | 1 | 1982 | 16 | 0.010 |
Why?
|
| Levodopa | 1 | 1982 | 12 | 0.010 |
Why?
|
| Cell Survival | 1 | 1985 | 901 | 0.010 |
Why?
|
| Daunorubicin | 1 | 1982 | 20 | 0.010 |
Why?
|
| Dicarboxylic Acids | 1 | 1982 | 16 | 0.010 |
Why?
|
| Allergens | 1 | 1982 | 54 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1982 | 32 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2007 | 2673 | 0.010 |
Why?
|
| Immunoglobulin E | 1 | 1982 | 91 | 0.010 |
Why?
|
| Ferrochelatase | 1 | 1981 | 1 | 0.010 |
Why?
|
| Uroporphyrinogen Decarboxylase | 1 | 1981 | 1 | 0.010 |
Why?
|
| Flavoproteins | 1 | 1981 | 4 | 0.010 |
Why?
|
| Protoporphyrinogen Oxidase | 1 | 1981 | 2 | 0.010 |
Why?
|
| Protoporphyrins | 1 | 1981 | 10 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1982 | 77 | 0.010 |
Why?
|
| Cell Communication | 1 | 1982 | 116 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1982 | 132 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 1982 | 142 | 0.010 |
Why?
|
| Prurigo | 1 | 1981 | 1 | 0.010 |
Why?
|
| Rosacea | 1 | 1981 | 5 | 0.010 |
Why?
|
| Hirsutism | 1 | 1981 | 6 | 0.010 |
Why?
|
| Tinea Versicolor | 1 | 1981 | 3 | 0.010 |
Why?
|
| Warts | 1 | 1981 | 6 | 0.010 |
Why?
|
| Skin Pigmentation | 1 | 1981 | 25 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 1981 | 117 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1982 | 304 | 0.010 |
Why?
|
| Antiparasitic Agents | 1 | 1981 | 12 | 0.010 |
Why?
|
| Mitochondrial Proteins | 1 | 1981 | 113 | 0.010 |
Why?
|
| Keratoacanthoma | 1 | 1981 | 8 | 0.010 |
Why?
|
| Lichen Planus | 1 | 1981 | 17 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1981 | 79 | 0.010 |
Why?
|
| Isotretinoin | 1 | 1980 | 8 | 0.010 |
Why?
|
| Cimetidine | 1 | 1980 | 25 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1981 | 282 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1982 | 135 | 0.010 |
Why?
|
| Dipyridamole | 1 | 1980 | 26 | 0.010 |
Why?
|
| Ultraviolet Therapy | 1 | 1980 | 9 | 0.010 |
Why?
|
| Triamcinolone Acetonide | 1 | 1980 | 10 | 0.010 |
Why?
|
| Minocycline | 1 | 1981 | 61 | 0.010 |
Why?
|
| Gonorrhea | 1 | 1981 | 50 | 0.010 |
Why?
|
| Chemotactic Factors | 1 | 1980 | 14 | 0.010 |
Why?
|
| Furocoumarins | 1 | 1980 | 9 | 0.010 |
Why?
|
| Lithium Carbonate | 1 | 1980 | 31 | 0.010 |
Why?
|
| Ether | 1 | 1980 | 2 | 0.010 |
Why?
|
| Nucleosides | 1 | 1980 | 9 | 0.010 |
Why?
|
| Vidarabine | 1 | 1980 | 12 | 0.010 |
Why?
|
| Lithium | 1 | 1980 | 76 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1980 | 48 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1980 | 129 | 0.010 |
Why?
|
| Prednisone | 1 | 1980 | 104 | 0.010 |
Why?
|
| Antibodies | 1 | 1981 | 241 | 0.010 |
Why?
|
| Myositis | 1 | 1980 | 24 | 0.010 |
Why?
|
| Peritoneal Dialysis | 1 | 1980 | 30 | 0.010 |
Why?
|
| Sjogren's Syndrome | 1 | 1980 | 18 | 0.010 |
Why?
|
| Dermatomyositis | 1 | 1980 | 31 | 0.010 |
Why?
|
| Urticaria | 1 | 1981 | 84 | 0.010 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1980 | 150 | 0.010 |
Why?
|
| Pituitary-Adrenal System | 1 | 1980 | 138 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 1982 | 269 | 0.010 |
Why?
|
| Bowen's Disease | 1 | 1979 | 6 | 0.010 |
Why?
|
| Methods | 1 | 1979 | 156 | 0.010 |
Why?
|
| Arthritis | 1 | 1980 | 53 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1982 | 481 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1981 | 193 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 1979 | 47 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 1979 | 91 | 0.010 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1980 | 91 | 0.010 |
Why?
|
| Neutrophils | 1 | 1980 | 204 | 0.010 |
Why?
|
| Aspirin | 1 | 1980 | 295 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 1979 | 120 | 0.010 |
Why?
|
| Arthrodermataceae | 1 | 1998 | 4 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1980 | 199 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1980 | 329 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1981 | 301 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 567 | 0.010 |
Why?
|
| Animals | 2 | 1982 | 20881 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 1994 | 9 | 0.010 |
Why?
|
| Infant | 1 | 1980 | 2891 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1994 | 46 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1994 | 86 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1980 | 1026 | 0.010 |
Why?
|
| Eyelid Diseases | 1 | 1993 | 7 | 0.010 |
Why?
|
| Retinoids | 1 | 1994 | 122 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1994 | 951 | 0.010 |
Why?
|
| Mice | 1 | 1982 | 8474 | 0.010 |
Why?
|
| Autoanalysis | 1 | 1988 | 11 | 0.010 |
Why?
|
| Immunologic Tests | 1 | 1987 | 9 | 0.000 |
Why?
|
| Hair | 1 | 1987 | 46 | 0.000 |
Why?
|
| Scalp | 1 | 1987 | 47 | 0.000 |
Why?
|
| Placebos | 1 | 1987 | 195 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1994 | 1070 | 0.000 |
Why?
|
| Mitogens | 1 | 1984 | 45 | 0.000 |
Why?
|